不明来源栓塞性卒中后心房颤动的预测因素:RE-SPECT ESUS 试验分析
RE-SPECT ESUS 试验纳入 5390 例不明来源栓塞性卒中患者,随访中位 19 个月,403 例(7.5%)发现心房颤动。多变量分析显示,年龄、高血压、体重指数和不伴糖尿病是心房颤动的独立预测因素;在基线 NT-proBNP 可用的亚组中,仅年龄和 NT-proBNP 升高有独立预测作用。
要点
- 年龄是心房颤动最强的独立预测因素,每增加 10 岁 OR 为 1.99。
- 高血压和较高体重指数增加心房颤动风险,糖尿病反而与较低风险相关。
- 基线 NT-proBNP 可用时,仅年龄和 NT-proBNP 升高独立预测心房颤动。
核心结论
- 除年龄外,高血压、较高体重指数和不伴糖尿病是不明来源栓塞性卒中后心房颤动的独立预测因素。
- 当基线 NT-proBNP 可用时,仅年龄和 NT-proBNP 升高可独立预测后续心房颤动。
研究设计与样本
- RE-SPECT ESUS 为随机对照试验,在 42 个国家 564 个中心比较达比加群酯与阿司匹林用于不明来源栓塞性卒中后二级预防。
- 共纳入 5390 例患者,随访中位 19 个月,403 例(7.5%)发现心房颤动。
主要发现
- 多变量模型中,年龄每增加 10 岁 OR 1.99(95%CI 1.78-2.23,P<0.001),高血压 OR 1.36(95%CI 1.03-1.79,P=0.0304),糖尿病 OR 0.74(95%CI 0.56-0.96,P=0.022),体重指数每增加 5 单位 OR 1.29(95%CI 1.16-1.43,P<0.001)。
- 基线 NT-proBNP 可用的 1117 例患者中,仅年龄和 NT-proBNP 升高是心房颤动的显著独立预测因素。
- HAVOC 和 CHA2DS2-VASc 评分越高,心房颤动发生率越高。
临床怎么用
- 可利用年龄、高血压、体重指数等基线因素识别不明来源栓塞性卒中后心房颤动高风险患者。
- 对高风险患者可考虑更密集的长期心脏监测以发现心房颤动。
局限性
- 心房颤动通过不良事件报告或常规临床心脏监测发现,可能低估真实发生率。
- NT-proBNP 分析仅限基线有测量的 1117 例患者,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A proportion of patients with embolic stroke of undetermined source have silent atrial fibrillation (AF) or develop AF after the initial evaluation. Better understanding of the risk for development of AF is critical to implement optimal monitoring strategies with the goal of preventing recurrent stroke attributable to underlying AF. The RE-SPECT ESUS trial (Randomized, Double-Blind Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) provides an opportunity to assess predictors for developing AF and associated recurrent stroke. METHODS: RE-SPECT ESUS was a randomized, controlled trial (564 sites, 42 countries) assessing dabigatran versus aspirin for the prevention of recurrent stroke in patients with embolic stroke of undetermined source. Of 5390 patients enrolled and followed for a median of 19 months, 403 (7.5%) were found to develop AF reported as an adverse event or using cardiac monitoring per standard clinical care. Univariable and multivariable regression analyses were performed to define predictors of AF. RESULTS: In the multivariable model, older age (odds ratio for 10-year increase, 1.99 [95% CI, 1.78-2.23]; P<0.001), hypertension (odds ratio, 1.36 [95% CI, 1.03-1.79]; P=0.0304), diabetes (odds ratio, 0.74 [95% CI, 0.56-0.96]; P=0.022), and body mass index (odds ratio for 5-U increase, 1.29 [95% CI, 1.16-1.43]; P<0.001) were independent predictors of AF during the study. In a sensitivity analysis restricted to 1117 patients with baseline NT-proBNP (N-terminal prohormone of brain natriuretic peptide) measurements, only older age and higher NT-proBNP were significant independent predictors of AF. Performance of several published predictive models was assessed, including HAVOC (AF risk score based on hypertension, age ≥75 years, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, and coronary artery disease) and CHA2DS2-VASc (stroke risk score based on congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, previous stroke, transient ischemic attack or thromboembolism [doubled], vascular disease, age 65 to 74 years, and sex category [female]) scores, and higher scores were associated with higher rates of developing AF. CONCLUSIONS: Besides age, the most important variable, several other factors, including hypertension, higher body mass index, and lack of diabetes, are independent predictors of AF after embolic stroke of undetermined source. When baseline NT-proBNP was available, only older age and elevation of this biomarker were predictive of subsequent AF. Understanding who is at higher risk of developing AF will assist in identifying patients who may benefit from more intense, long-term cardiac monitoring. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02239120.
引用
- Bahit MC, Sacco RL, Easton JD, et al. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. Circulation. 2021. PMID: 34649459. doi:10.1161/CIRCULATIONAHA.121.055176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。